ENTX vs. CADL, ESLA, PLUR, NKGN, TARA, OKYO, DTIL, QNCX, CYTH, and CASI
Should you be buying Entera Bio stock or one of its competitors? The main competitors of Entera Bio include Candel Therapeutics (CADL), Estrella Immunopharma (ESLA), Pluri (PLUR), NKGen Biotech (NKGN), Protara Therapeutics (TARA), OKYO Pharma (OKYO), Precision BioSciences (DTIL), Quince Therapeutics (QNCX), Cyclo Therapeutics (CYTH), and CASI Pharmaceuticals (CASI). These companies are all part of the "biological products, except diagnostic" industry.
Entera Bio (NASDAQ:ENTX) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.
Entera Bio has higher revenue and earnings than Candel Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Entera Bio has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500.
Candel Therapeutics' return on equity of -90.47% beat Entera Bio's return on equity.
Entera Bio received 164 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Entera Bio an outperform vote while only 50.00% of users gave Candel Therapeutics an outperform vote.
In the previous week, Candel Therapeutics had 2 more articles in the media than Entera Bio. MarketBeat recorded 6 mentions for Candel Therapeutics and 4 mentions for Entera Bio. Candel Therapeutics' average media sentiment score of 0.33 beat Entera Bio's score of 0.02 indicating that Candel Therapeutics is being referred to more favorably in the news media.
14.1% of Entera Bio shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 8.9% of Entera Bio shares are held by company insiders. Comparatively, 44.6% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Entera Bio presently has a consensus price target of $10.00, indicating a potential upside of 498.80%. Candel Therapeutics has a consensus price target of $9.00, indicating a potential upside of 469.62%. Given Entera Bio's higher possible upside, equities research analysts clearly believe Entera Bio is more favorable than Candel Therapeutics.
Summary
Entera Bio and Candel Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Entera Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Entera Bio Competitors List
Related Companies and Tools